Stay updated with breaking news from View Release. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter...
Marketplace-ul de influenceri locali FameUP fondat de un antreprenor din Iași a obținut o finanțare seed de 2,5 milioane de euro, de la un grup de investitori din care fac parte fondul Early Game Ventures și fondatorul UiPath Daniel Dines.
STIRIPESURSE.RO vă prezintă actele normative adoptate de Guvern în ședința din 29 iunie 2021. Ședința a avut loc la scurt timp după ce parlamentarii au votat moțiunea de cenzură depusă de PSD împotriva cabinetului Florin Cîțu. Din cele 234 de voturi necesare, moțiunea a strâns doar 201. I. PROIECTE DE LEGE 1. PROIECT DE LEGE pentru modificarea şi completarea Anexei la Legea nr. 339/2005 privind regimul juridic al plantelor, substanțelor şi preparatelor stupefiante şi psihotrope 2. PROIECT DE LEGE pentru modificarea şi completarea Ordonanței de urgență a Guvernului nr. ...
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor News provided by Share this article Share this article SAN DIEGO...
Share this article Share this article SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across its clinical and discovery pipeline and strength as it expands its operational structure and capabilities in preparation for potential commercialization in the United States. "Our commitment to patients with cancer has enabled us to advance our two clinical programs, adagrasib and sitravatinib, as well as our pr...